↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Seaport Entertainment Group$SEG · filed: grew revenue 18.3% in FY2025 to $130MOld boatNext year $118M–$169M sealedCheck ▾Close ▴
What Seaport Entertainment Group filed
Grew revenue 18.3% in FY2025 to $130 million, operating margin -90.6% against a 7.0% median for miscellaneous amusement & recreation, equity 70.2% of assets. Every figure links to the filing it came from on Seaport Entertainment Group’s card. Old boat: three warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $118M and $169M, an 80% range sealed on 27 Sept 2026 · receipt #6562a9 · graded in public by the revenue in Seaport Entertainment Group’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Three biotech IPOs in one day—Kailera priced, Seaport and Hemab filed—test whether allocators will pay 2025 premiums or only distressed exits.
$210 million
IPO pricing on the same trading day
$225 million
across three private rounds since inception in 2020
$102 million
in a Series C led by OrbiMed and Qiming…
$14.00
the midpoint of its range
Seaport Therapeutics and Hemab filed S-1 registration statements with the SEC within hours of each other, following Kailera's $210 million IPO pricing on the same trading day. The cluster marks the most concentrated biotech offering activity since Q1 2023, when fourteen healthcare companies pulledfilings after SVB's collapse.
Seaport, a neuroscience-focused developer backed by Atlas Venture and Frazier Life Sciences, is advancing SPN-830 for post-traumatic stress disorder and major depressive disorder. The Cambridge firm raised $225 million across three private rounds since inception in 2020. Hemab, developing hemophilia A therapies out of Shanghai and Boston, last raised $102 million in a Series C led by OrbiMed and Qiming Venture Partners in late 2022. Neither company disclosed offering size or valuation range in initial filings. Kailera, a gene therapy platform targeting kidney disease, priced 15 million shares at $14.00, the midpoint of its range, after narrowing guidance twice during roadshow.
The timing reflects two tactical shifts. First, Kailera's oversubscribed book—despite pricing below its July 2023 Series D valuation of $820 million—gives syndicate desks a live comp for loss-making assets with Phase II data. Seaport's lead program reported topline results in December showing statistically significant PTSD symptom reduction versus placebo; Hemab's HMB-001 is in Phase I/II trials with interim data expected Q2 2025. Second, the three-month Treasury yield dropped 47 basis points since October, compressing biotech discount rates enough to make 2026-27 monetization timelines viable again for crossover funds holding late-stage positions. OrbiMed, a common thread across all three cap tables, is sitting on $3.2 billion in unrealized life sciences positions per its Q3 2024 ADV filing.
The reopening is conditional. Biotech IPO proceeds totaled $1.8 billion in 2024, down 72 percent from 2021's $6.4 billion. The companies filing now are those with twelve-plus months of runway and catalysts landing before capital markets could freeze again. Seaport's cash position as of September 30 was $187 million, sufficient through mid-2026 without additional financing. Hemab's runway is tighter—$68 million in cash against a $9 million monthly burn as of its last disclosed financials in March 2024. That asymmetry suggests Hemab is testing whether investors will pay for earlier-stage China-US dual development risk, or whether it becomes a June withdrawal.
Allocators should track three variables over the next forty-five days. First, whether Seaport and Hemab price within 15 percent of their last private rounds—anything steeper signals the window is open only at distress levels. Second, whether either company expands offering size during roadshow, indicating genuine institutional demand rather than insider-backstopped survival rounds. Third, the performance of Kailera's stock through its first earnings report in May; if it trades below issue price after data updates, syndicates will reprice risk across the entire neuroscience and rare disease cohort. Two more S-1s are expected from VC-backed biotechs before April, both filed confidentially in Q4 2024.
The Kailera pricing matters less for its $210 million gross than for proving a single biotech company could clear underwriters' risk committees in March 2025. The next thirty days determine whether that was an exit, or a reopening.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
